HAPILA and Transo-Pharm cement partnership with joint synthesis announcement at CPHI Frankfurt 2025
Combined HAPILA and Transo-Pharm Handels-GmbH team: (L-R) Frank Krause (Managing Director Transo-Pharm), Timo Krabiell (Transo-Pharm), Dr. Uwe Müller (Managing Director HAPILA GmbH), Jessica Ha (Transo-Pharm), Dr. Richard Nohl (HAPILA), Dr. Steffen Wittmann (HAPILA), Geng Xiding (Transo-Pharm)
The strategic partnership between high-potency active ingredient specialist CDMO HAPILA GmbH and global marketing and distribution partner Transo-Pharm Handels-GmbH, will be again present at their shared stand (Booth C80, Hall 11.0, API Zone) at Messe Frankfurt during the CPHI Worldwide (October28th-30th). Strengthening their collaboration, the stand will feature details of the commissioning of a new GMP plant at HAPILA’s Thuringia site for the commercial-scale production of API to fulfill all customers current and prospective expectations regarding quality and quantity “Made in Germany”. The facility has now come online in September 2025.
© 2026 HAPILA GmbH
Diese Webseite verwendet keine Tracking Tools. Durch Ihren Browser wird ein funktional notwendiges Cookie als Lesebestätigung gespeichert. Unsere Datenschutzrichtline enthält dazu weitere Details.
This website does not use any tracking tools. Your browser stores a cookie that is necessary for functionality to confirm that you have read this notice. Our Privacy Policy contains further details.
